Natural products are considered to be good sources for the screening of lead compounds of clinical drugs. We performed a large number of drug screenings by using a variety of assay systems with crude extracts of microbial cultures as a traditional natural product library. In some assay systems, our crude extract library could not work effectively. With this in mind, we started to construct a purified natural compound library possessing various skeletons from cultures of microorganisms. As actinomycetes are known to produce pharmaceutically useful compounds, 1,2 we focused mainly on secondary metabolites from cultures of actinomycetes. To achieve this, we established a high-throughput system for the detection of secondary metabolites from the cultures of actinomycetes with the retentiontime and HR-MS data of known compounds by using a UPLC-TOF-MS system (Waters, Milford, MA, USA). 3 We analyzed the secondary metabolites, including potential novel compounds, present in the cultures of the strains isolated from a variety of resources by this system. 3 In the course of our chemical screening program, a new furaquinocin derivative named JBIR-136 (1, Figure 1a), together with the known compound kujimycin A, 4 was isolated from a culture broth of Streptomyces sp. 4963H2. This paper describes the fermentation, isolation, structural elucidation and, in brief, the biological activity of 1.Streptomyces sp. 4963H2 was isolated from a soil sample collected in Kimitsu, Chiba Prefecture, Japan. The strain was cultivated in 50-ml test tubes, each containing 15 ml of a seed medium consisting of 1.0% starch (Kosokagaku, Tokyo, Japan), 1.0% polypeptone (Nihon Pharmaceutical, Tokyo, Japan), 1.0% molasses (Dai-Nippon Meiji Sugar, Tokyo, Japan) and 1.0% meat extract (Extract Ehlrich, Wako Pure Chemical Industry, Osaka, Japan) at pH 7.2 (adjusted before sterilization). The test tubes were shaken on a reciprocal shaker (320 r.p.m.) at 27 1C for 2 days. Aliquots (2.5 ml) of the broth were transferred to 500-ml baffled Erlenmeyer flasks containing 100 ml of a production medium consisting of 2.0% glycerol (Nacalai Tesque, Kyoto, Japan), 1.0% molasses (Dai-Nippon Meiji Sugar), 0.5% casein (Kanto Chemical, Tokyo, Japan), 0.1% polypeptone (Nihon Pharmaceutical) and 0.4% CaCO 3 (Kozaki Pharmaceutical, Tokyo, Japan) at pH 7.2 (adjusted before sterilization), and were cultured on a rotary shaker (180 r.p.m.) at 27 1C for 5 days.The fermentation broth (2 l) was separated by centrifugation. The supernatant was partitioned between EtOAc and H 2 O (2l 3), whereas the mycelial cake was extracted with acetone (50 ml) and filtered, and the filtrate was concentrated in vacuo. The residual aqueous concentrate was extracted with EtOAc (equal volume  3). The combined EtOAc layers were dried over Na 2 SO 4 , and then evaporated to dryness. The residue (733 mg) was subjected to normalphase medium pressure liquid chromatography (Purif-Pack SI-30, Shoko Scientific, Yokohama, Japan) and developed successively with a gradient system of n-hexane-EtOAc (0-15% E...